Yann Godbert is an expert in Endocrinology at Institut Bergonié (France). Yann Godbert has authored 87 publications, the most recent in 2026, and is an investigator in 14 clinical trials, 1 of them ongoing. SLR score: 416 (community average: 125). How the SLR is computed.

LeadR Profile

Yann Godbert Institut Bergonié France
416 ScienceLeadR Reputation 416
Network Map

Endocrinology

Subspecialties: Oncology - Nuclear Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Source: PubMed

Institut Bergonié

2013 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 87

Citations

Citations: 2 558 1st author: 7 Last author: 11 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Lymphopenia and Circulating Biomarker Dynamics Associated with Clinical Outcome and Toxicity in Pazopanib-Treated Radioiodine-Refractory Thyroid Cancer: Exploratory Analyses from the Pazothyr Trial.
PMID 43007078 — cytokines, cells, thyroid diseases, growth, vascular endothelial growth factor a, lymphopenia, neoplasms, interleukin-6, thyroid gland, biomarkers, thyroid neoplasms, therapeutics, thyroid hormones, plasma
Thyroid20260
Real-World Outcomes of [ 177Lu]Lu-PSMA-617 in the French Early-Access Program for Patients with Metastatic Castration-Resistant Prostate Cancer.
PMID 42562607 — safety, androgens, receptors, androgen, neoplasms, prostate, drug therapy, aged, neoplasm metastasis, prostatic neoplasms, castration, therapeutics, chemotherapy
J Nucl Med20260
Complete Radiologic Response After 177Lu-DOTATATE Therapy in Treatment of a Lung Metastatic Intracranial Atypical Meningioma.
PMID 40739709 — lung, somatostatin, meningioma, therapeutics
Clin Nucl Med20250
ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer.
PMID 40345488 — endocrinology, neoplasms, thyroid gland, thyroid neoplasms, therapeutics
Ann Endocrinol (Paris)20250
ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer.
PMID 40288439 — endocrinology, neoplasms, multiple chronic conditions, thyroid gland, thyroid neoplasms, therapeutics, prognosis
Ann Endocrinol (Paris)20251

Clinical Studies 14

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 2 6
Phase 3 5
Phase 1/Phase 2 2
N/A 1

By status:

Active not recruiting 4
Completed 4
Recruiting 3
Unknown 2
Terminated 1

By type:

Interventional 14

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 2
multicentric5to9 1
multicentricup10 8

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Intra arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP NET Patients With Dominant Liver Metastases
NCT04837885 — injections, somatostatin, tomography, administration, intravenous, positron-emission tomography, neoplasms, positron emission tomography computed tomography, liver, liver neoplasms, neoplasm metastasis, neuroendocrine tumors, therapeutics, receptors, peptide, injections, intravenous
Phase 2Recruiting2021

LeadR Networks

Main global connection map